REDWOOD CITY, Calif., Nov. 9 /PRNewswire/ -- Perclose, Inc. (Nasdaq: PERC)
today announced it is sending a supplement dated November 8, 1999 to its proxy
statement dated August 26, 1999 containing information regarding an agreement
recently reached between Abbott Laboratories and the U. S. Food and Drug
Administration. The proxy supplement also contains updated financial
information and information about Perclose's adjourned stockholders' meeting
scheduled for November 19, 1999 at 8:00 a.m. at Perclose's corporate
headquarters located at 400 Saginaw Drive Redwood City, CA 94063.
Perclose, based in Redwood City, California, was founded in 1992 and
designs, manufactures and markets less invasive medical devices that automate
the surgical closure or connection of blood vessels. The Prostar(R),
Techstar(R) and Heartflo(TM) products use a platform technology that allows
hand held devices to remotely, automatically and precisely deploy needles and
sutures for vascular repair. The surgical approach that the Prostar(R) and
Techstar(R) products use distinguishes them from the limited number of
competitors in the femoral artery closure device product category.
The Prostar(R) products, marketed in the U.S. and internationally,
surgically close the arterial access site in the femoral artery following
catheterization procedures such as angioplasty, stenting and atherectomy. The
Techstar(R) products, also marketed worldwide, surgically close the arterial
access site in the femoral artery following diagnostic angiography procedures.
These patented, proprietary products offer superior clinical treatment, more
rapid recovery and a lower treatment cost alternative to the standard method
of closing arterial access sites. The Heartflo(TM) System, which is designed
to automate the surgical connection of blood vessels during conventional and
minimally invasive coronary artery bypass surgery, is in development.
Perclose common stock is traded on the Nasdaq National Market under the symbol
PERC.
For general information on Perclose via fax at no cost, call 800-PRO-INFO,
ticker symbol PERC.
SOURCE Perclose, Inc.
 back to top
CONTACT:
Ken Ludlum, Chief Financial Officer of
Perclose, Inc., 650-474-3000, or general, Traci McCarty, or
analysts, Janet Nelson, both of The Financial Relations Board,
415-986-1591
|
